Leadership changes to fuel startup growth

Longevity startup Biolytica has the vision of becoming the leading data platform for preventive healthcare and longevity. It developed an AI-driven analytics platform, NEXUS health data, that aggregates, visualizes and analyzes data from genomics, blood and epigenetic biomarkers, as well as microbiome biomarkers, wearable devices, lifestyle data and more. With its new CEO Arndt Rolfs, the startup is set to turbocharge its growth. Rolfs is a Professor for Neurology and Psychiatry holds a distinguished reputation as a globally active medical expert and stands as a prominent leader in the research and clinical topics of complex genetic diseases. He has developed identified and characterized innovative medical biomarkers to predict diseases and potential health problems. With his multi-entrepreneurial spirit, he has founded several global biotechnology and healthcare ventures over the past two decades, significantly shaping the transformation of the global health prevention ecosystem. In his free time, he loves arranging classical music and operas, enjoying the German countryside and playing chess.

Arndt will especially take the responsibility to implement the most modern Omics-technologies like metabolomics in the longevity and preventive medicine transformation process of Biolytica. “The combination of digital platforms, modern omicstechnologies like metabolomics, proteomics and microbiomics with AI will drive the transformation of our healthcare system and will support all longevity concepts”, said Arndt. Arndt’s predecessor, Dr. Robert Konrad Maciejewski, will seamlessly transition into the role of Co-CEO and CBO to take Biolytica’s business development to the next level.

SonarSource Co-CEO
SonarSource, the leading Clean Code solution provider helping organizations increase innovation and productivity while decreasing business risk and technical debt, has welcomed Tariq Shaukat as co-Chief Executive Officer (CEO) along with Founder and CEO Olivier Gaudin. He will also join the Board of Directors. Tariq has extensive experience in growing and scaling private and public companies across diverse industries. Coupled with Olivier’s technical and market vision, the partnership will become a formidable force in the industry. Tariq’s experience spans many domains, including enterprise and consumer software, cloud infrastructure, retail, travel, and entertainment. Before joining Sonar, he served as President of Bumble Inc. from July 2020 to August 2023, helping to lead the company’s successful public offering on the NASDAQ stock exchange in 2021. While at Bumble, he led company operations and partnered with the Founder and CEO to scale the company to over $900M in revenue in 2022. Before that, Tariq was the President of Google Cloud from 2016 to 2020 and played a crucial role in scaling the business to over US$ 10B in ARR. Sonar is trusted by more than 500,000 organizations and used by more than 7 million developers globally. It has also generated profitable growth with more than US$ 200M in revenue. Tariq will support the company in keeping up with its growth rate.

Oculis appoints new CCO
Rebecca Weil is the new Chief Commercial Officer of Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care with clinical-stage pipeline comprising multiple drug candidates in development for eye diseases of high unmet need. Weil is a seasoned commercial executive with 20 years of experience in biotech and large pharmaceutical companies at the global, regional, and local levels. Prior to joining Oculis, she was the Senior Vice President, Head of Global Marketing for Idorsia where she built the team, defined the go-to-market strategies and launched the company’s first two products. Ms. Weil started her career in strategic consulting at McKinsey & Company, and held commercial leadership positions at Novartis, Bausch + Lomb, Alcon and Shire where she led the global ophthalmology and neuroscience franchises and product launch strategy development. In her new role, Ms. Weil will lead the organization to commercial readiness from designing launch strategies for U.S. and globally and building the required commercial infrastructure to bring all of Oculis’ groundbreaking ophthalmic product candidates to markets worldwide.

(RAN)